Olema Pharmaceuticals (OLMA) Cash from Operations (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Cash from Operations of 45987000.0 for Q1 2026, down 4.57% year-over-year from 48187135.71 in Q1 2025, and down 19.99% quarter-over-quarter from 38327000.0 in Q4 2025.
Olema Pharmaceuticals (OLMA) Cash from Operations (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Cash from Operations for 7 consecutive years, with 45987000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 4.57% year-over-year to 45987000.0; the TTM figure through Mar 2026 stood at 148724000.0 (down 19.14% YoY), while the FY2025 annual figure was 146716000.0, down 40.6% from the prior year.
- Cash from Operations eased to 45987000.0 in Q1 2026 per OLMA's latest filing, from 38327000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 17903000.0 in Q1 2022 and bottomed at 45987000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 27226235.29 across 5 years, with a median of 26284000.0 in 2024.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 197.13% — and 2023, when it increased 16.41%.
- Olema Pharmaceuticals' Cash from Operations stood at 19711000.0 in 2022, then increased by 6.27% to 18476000.0 in 2023, then tumbled by 42.26% to 26284000.0 in 2024, then slumped by 45.82% to 38327000.0 in 2025, then decreased by 19.99% to 45987000.0 in 2026.
- Business Quant data shows OLMA's Cash from Operations at 45987000.0 in Q1 2026, 38327000.0 in Q4 2025, and 34527000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Olema Pharmaceuticals | 930.10 Mn | 930.10 Mn | - | -45.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -45.90 Mn |
| Jun 30, 2026 | -45.90 Mn |
| Mar 31, 2026 | -45.99 Mn |
| Mar 31, 2026 | -45.99 Mn |
| Dec 31, 2025 | -38.33 Mn |
| Dec 31, 2025 | -38.33 Mn |
| Sep 30, 2025 | -34.53 Mn |
| Sep 30, 2025 | -34.53 Mn |
| Jun 30, 2025 | -29.88 Mn |
| Jun 30, 2025 | -29.88 Mn |
| Mar 31, 2025 | -43.98 Mn |
| Mar 31, 2025 | -43.98 Mn |
| Dec 31, 2024 | -26.28 Mn |
| Dec 31, 2024 | -26.28 Mn |
| Sep 30, 2024 | -27.02 Mn |
| Sep 30, 2024 | -27.02 Mn |
| Jun 30, 2024 | -27.56 Mn |
| Jun 30, 2024 | -27.56 Mn |
| Mar 31, 2024 | -23.50 Mn |
| Mar 31, 2024 | -23.50 Mn |